How much do paid clinical trials in Reading pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Do I need to be sick to join a clinical trial in Reading?

No. Many studies recruit healthy volunteers, especially early-phase studies run at dedicated research centers. Others need participants diagnosed with a specific condition. Every trial lists its eligibility criteria — age range, condition, medications — and the study team screens you before enrollment.

Are clinical trials in Reading safe?

Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.

How do I join a study in Reading, PA?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

What is the difference between a research center and a hospital study in Reading?

Dedicated research centers (listed on this page with their Google ratings) run studies as their core business — often healthy-volunteer and vaccine studies with structured compensation. Hospital and university studies tend to focus on patients with specific conditions. Both types are registered and IRB-supervised.

Paid Clinical Trials Reading, PA — 281 Studies Recruiting (Jul 2026)

St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic

Cervical Cancer Screening N/A Interventional 50 participants sought

Penn State Health St. Joseph's — Reading, Pennsylvania (0.3 mi) · Sponsor: Milton S. Hershey Medical Center

See eligibility & contact on ClinicalTrials.gov (NCT05092022)

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Active Rheumatoid Arthritis Phase 2 Interventional 180 participants sought

Pennsylvania Regional Center for Arthritis & Osteoporosis Research — Wyomissing, Pennsylvania (2.2 mi) · Sponsor: Elevara Medicines Limited

See eligibility & contact on ClinicalTrials.gov (NCT07409103)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Ganglioneuroblastoma, Nodular, Neuroblastoma Phase 3 Interventional 478 participants sought

Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania (29.5 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06172296)

Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes

Diabetes Mellitus, Type 2, Diabetes Education N/A Interventional 65 participants sought

Reading Hospital, an affiliate of Tower Health — West Reading, Pennsylvania (1.2 mi) · Sponsor: The Reading Hospital and Medical Center

See eligibility & contact on ClinicalTrials.gov (NCT05893927)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Interventional 1,450 participants sought

Penn State Health Saint Joseph Medical Center — Reading, Pennsylvania (0.3 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

See eligibility & contact on ClinicalTrials.gov (NCT04566328)

Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age

Amblyopia Phase 3 Interventional 252 participants sought

Conestoga Eye — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Jaeb Center for Health Research

See eligibility & contact on ClinicalTrials.gov (NCT06524882)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm Phase 2 Interventional 2,000 participants sought

Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05564390)

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant Phase 3 Interventional 800 participants sought

Lehigh Valley Hospital — Allentown, Pennsylvania (29.5 mi) · Sponsor: Janssen Research & Development, LLC

See eligibility & contact on ClinicalTrials.gov (NCT07225946)

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Endometrial Cancer, Endometrioid Adenocarcinoma N/A Observational 1,715 participants sought

Lehigh Valley Health Network — Allentown, Pennsylvania (29.5 mi) · Sponsor: Memorial Sloan Kettering Cancer Center

See eligibility & contact on ClinicalTrials.gov (NCT04291612)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Breast Cancer, Early Breast Cancer Phase 3 Interventional 4,300 participants sought

Research Site — Reading, Pennsylvania (0.3 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT05774951)

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Phase 2, Phase 3 Interventional 613 participants sought

Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT01810913)

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Glioma Phase 2 Interventional 57 participants sought

Lehigh Valley Health Network (Data Collection Only) — Allentown, Pennsylvania (29.5 mi) · Sponsor: Memorial Sloan Kettering Cancer Center

See eligibility & contact on ClinicalTrials.gov (NCT05188508)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma N/A Interventional 1,956 participants sought

Lancaster General Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04251052)

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ Phase 3 Interventional 250 participants sought

Keystone Urology Specialists — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Ferring Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT06545955)

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma Phase 3 Interventional 62 participants sought

Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania (29.5 mi) · Sponsor: Children's Oncology Group

See eligibility & contact on ClinicalTrials.gov (NCT05235165)

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma Phase 2 Interventional 80 participants sought

Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania (29.5 mi) · Sponsor: Children's Oncology Group

See eligibility & contact on ClinicalTrials.gov (NCT02981628)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Breast Carcinoma, Colorectal Carcinoma N/A Observational 2,000 participants sought

Ephrata Cancer Center — Ephrata, Pennsylvania (17.3 mi) · Sponsor: Wake Forest University Health Sciences

See eligibility & contact on ClinicalTrials.gov (NCT06418204)

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer Phase 3 Interventional 780 participants sought

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068) — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Merck Sharp & Dohme LLC

See eligibility & contact on ClinicalTrials.gov (NCT06312137)

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease Phase 3 Interventional 410 participants sought

Local Institution - 1019 — Allentown, Pennsylvania (29.5 mi) · Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

See eligibility & contact on ClinicalTrials.gov (NCT05511363)

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

Neoplasms, Arteriovenous Malformation of Central Nervous System N/A Observational 50,000 participants sought

Pottstown Memorial Medical Center — Pottstown, Pennsylvania (16.0 mi) · Sponsor: The Radiosurgery Society

See eligibility & contact on ClinicalTrials.gov (NCT01885299)

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Peripartum Cardiomyopathy, Postpartum Phase 4 Interventional 250 participants sought

Lehigh Valley Health Network — Allentown, Pennsylvania (29.5 mi) · Sponsor: Dennis M. McNamara, MD, MS

See eligibility & contact on ClinicalTrials.gov (NCT05180773)

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Prostate Cancer (Adenocarcinoma) Phase 3 Interventional 830 participants sought

Geisinger Cancer Services-Pottsville — Pottsville, Pennsylvania (27.7 mi) · Sponsor: Canadian Cancer Trials Group

See eligibility & contact on ClinicalTrials.gov (NCT06592924)

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

Chronic Pain N/A Observational 2,000 participants sought

Center for Interventional Pain & Spine — Exton, Pennsylvania (26.9 mi) · Sponsor: Abbott Medical Devices

See eligibility & contact on ClinicalTrials.gov (NCT03876054)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer Phase 3 Interventional 1,670 participants sought

Ephrata Cancer Center — Ephrata, Pennsylvania (17.3 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04852887)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer, Cognitive Impairments N/A Interventional 386 participants sought

Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT05896189)

Paid Clinical Trials in Reading, PA

Studies recruiting near Reading right now